BioSpace News Archive

A new study shows that the less-invasive saliva test for COVID-19 gives just as accurate results as those of the nasopharyngeal specimen.

Cortexyme, Inc., a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, received a letter from the U.S. Food and Drug Administration stating that a partial clinical hold has been placed on atuzaginstat impacting the open-label extension phase of the company’s ongoing Phase 2/3 study, the GAIN Trial.